IGC Pharma 1 article

IGC Pharma is a neuropsychiatric therapeutics company developing cannabinoid-receptor-modulating medicines for Alzheimer-related symptoms. Its scientific profile is anchored in Alzheimer neuropsychiatric therapeutics and IGC-AD1 oral liquid therapy, with cannabinoid receptor type 1 modulation providing a more specific mechanistic or disease context. A further stable marker is behavioral symptoms of dementia therapeutics; neurodegenerative disease symptom therapy adds context without reducing IGC Pharma to a single asset or program.